Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Patel, C. Coupland, M. Stone, D. Hosking (1995)
Comparison of methods of assessing response of Paget's disease to bisphosphonate therapy.Bone, 16 2
C. Roux, C. Gennari, J. Farrerons, J. Devogelaer, H. Mulder, H. Kruse, C. Picot, L. Titeux, J. Reginster, M. Dougados (1995)
Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone.Arthritis and rheumatism, 38 6
L. Álvarez, N. Guañabens, P. Peris, S. Vidal, Inmaculada Ros, A. Monegal, J. Bedini, Ramón Deulofeu, F. Pons, J. Muñoz‐Gómez, Antonio Ballesta (2001)
Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.Bone, 29 5
A. Grauer, H. Bone, E. McCloskey, M. McClung, D. Gutteridge, K. Lyles, C. Mautalen, Gideon An, S. Wallach (1999)
Discussion: Newer bisphosphonates in the treatment of paget's disease of bone: Where we are and where we want to goJournal of Bone and Mineral Research, 14
L. Álvarez, C. Ricós, P. Peris, N. Guañabens, A. Monegal, F. Pons, A. Ballesta (2000)
Components of biological variation of biochemical markers of bone turnover in Paget's bone disease.Bone, 26 6
P. Miller, Jacques Brown, E. Siris, M. Hoseyni, D. Axelrod, P. Bekker (1999)
A randomized, double-blind comparison of risedronate and etidronate in the treatment of paget’s disease of boneThe American Journal of Medicine, 106
S. Khan, E. McCloskey, K. Nakatsuka, J. Orgee, G. Coombes, J. Kanis (1996)
Duration of response with oral clodronate in Paget's disease of bone.Bone, 18 2
P. Selby, M. Davie, S. Ralston, M. Stone (2002)
Guidelines on the management of Paget's disease of bone.Bone, 31 3
F. Pons, L. Álvarez, P. Peris, N. Guañabens, S. Vidal-Sicart, A. Monegal, J. Pavía, A. Ballesta, J. Muños-Gómez, R. Herranz (1999)
Quantitative evaluation of bone scintigraphy in the assessment of Paget's disease activity.Nuclear medicine communications, 20 6
L. Álvarez, P. Peris, Francisca Pons, N. Guañabens, Ramón Herranz, A. Monegal, José Bedini, Ramón Deulofeu, M. Osaba, J. Muñoz‐Gómez, Antonio Ballesta (1997)
Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity.Arthritis and rheumatism, 40 3
S. Papapoulos, M. Frölich (1996)
Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.The Journal of clinical endocrinology and metabolism, 81 11
Sanjeev Patel, M. Stone, C. Coupland, D. Hosking (1993)
Determinants of remission of paget's disease of boneJournal of Bone and Mineral Research, 8
Pierre Delmas, Pierre Meunier (1978)
MANAGEMENT OF PAGET’S DISEASE OF BONEInPharma, 119
I. Reid, G. Nicholson, R. Weinstein, D. Hosking, T. Cundy, M. Kotowicz, W. Murphy, S. Yeap, Suzanne Dufresne, A. Lombardi, T. Musliner, D. Thompson, A. Yates (1996)
Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial.The American journal of medicine, 101 4
Objectives. To monitor the long-term evolution of Paget's disease activity after treatment with tiludronate by using serum total alkaline phosphatase (TAP) and more sensitive markers such as bone alkaline phosphatase (BAP), procollagen type I N propeptide (PINP) and urinary N-terminal cross-linking telopeptide of type I collagen (NTX); to analyse the predictors of long-term response to therapy; and to study the most appropriate intervals of time for monitoring the response to therapy.Methods. Thirty-two patients with Paget's disease were included in the study. All received 400 mg of oral tiludronate daily for 3 months. A total of 21 patients completed the study. In these patients, serum TAP, BAP and PINP and urinary NTX were measured at baseline and at 1, 6, 12 and 24 months after discontinuation of therapy. Quantitative bone scintigraphy was performed at baseline and at 6 and 24 months after the end of treatment, obtaining a scintigraphic activity index (SAI). Patients were classified into two groups depending on the long-term response to treatment: Group 1, patients who presented a persistent and significant decrease in disease activity at this time, n = 12 (57%) and Group 2, patients who presented a relapse in the activity of the disease at 24 months after treatment, n = 9 (43%). The relapse of disease activity was defined as a significant increase of SAI (>13%) between 6 and 24 months after the end of treatment, whereas the response to therapy was defined as a significant reduction in SAI (>13%) at 6 months after the end of treatment. In addition, these results were compared with the biochemical evolution of bone markers.Results. Biochemical markers and SAI decreased significantly after therapy and the nadir response was observed at 6 months. At this time 100% of patients responded to therapy. The persistent long-term response was associated with lower baseline indices of bone turnover (serum BAP<60 ng/ml or TAP<600 IU/l). The intervals of time for monitoring depended on the marker used: no patient from Group 1 presented a biochemical relapse in serum TAP at 1 and 2 yr after the end of treatment whereas 33 and 45% of these patients showed relapsed serum BAP at these time points. Moreover, all patients from Group 2 presented a biochemical relapse of serum BAP at 2 yr whereas in only 33% of these patients did serum TAP relapse at this time.Conclusion. Most of the Pagetic patients treated with tiludronate presented a long-term response, which persisted 2 yr after the end of treatment. The nadir response to treatment was observed 6 months after discontinuation of therapy whereas the relapse of disease activity was already observed 1 yr after the end of therapy and depended on both the baseline disease activity and the bone marker used in the evaluation.
Rheumatology – Oxford University Press
Published: Jul 30, 2004
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.